Add 3 more biotechs to the IPO list: Agile, Aldeyra and GlobeImmune
Three more biotechs are aiming for IPOs amid a frenzy of public offerings in the industry. Agile Therapeutics, Aldeyra Therapeutics and GlobeImmune are hoping to raise a combined $132 million.
Eager biotechs eye $133M in IPOs as a frenzied quarter closes
Three more drug developers are angling to go public in the waning days of a bustling first quarter for biotech IPOs, swinging for a combined $133 million to bankroll their programs. Agile Therapeutics, Aldeyra Therapeutics and GlobeImmune have all queued up for Wall Street debuts, hoping 2014's bull market lasts long enough to pull off offerings.
GlobeImmune pulls plug on $75M IPO despite still-bubbling market
After repeated delays, Colorado immunotherapy developer GlobeImmune has finally called it quits on plans to raise up to $74.8 million in an IPO, citing poor market conditions amid a prolonged boom in biotech debuts.
GlobeImmune has detailed plans for a $69 million IPO, aiming to rally public investors to back development of its therapeutic vaccines.
GlobeImmune's $69M IPO designed to build immunotherapy pipeline
GlobeImmune is hoping to ride the new wave of enthusiasm over immunotherapies to a successful IPO designed to raise up to $69 million.
Developing proteomic signatures focus pancreatic cancer therapy
Biodesix, a Boulder, CO-based company developing diagnostics based on mass spectrometry technology, has found a proteomic signature after its analysis of a clinical trial of GlobeImmune's GI-4000 cancer vaccine in pancreatic cancer.
Gilead Sciences ($GILD) is giving GlobeImmune an undisclosed upfront payment for early development and funding to support continued development of its hepatitis B virus (HBV) therapeutic vaccine
Good news for GlobeImmune and its Tarmogen vaccine platform: the company released positive safety and immunogenicity data for GI-4000 and GI-6207, which treat lung adenocarcinoma and carcinoembryonic
GlobeImmune's GI-5005, the company's investigational Tarmogen product, improved sustained virologic response by 12 percent in patients with genotype 1 chronic hepatitis C virus infection who had
GlobeImmune cuts 25% of staff
Roughly six months after raising $17.5 million for Phase III work, Louisville, CO-based GlobeImmune says it has laid of 15 of its 60 employees--or 25 percent. "Basically we were adjusting the